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INTRODUCTION
Major histocompatibility complex class II transactivator
(CIITA), a non-DNA-binding transcription factor, is required
for expression of MHC class II and other genes related to anti-
gen (Ag) presentation in both conventional and non-conven-
tional antigen-presenting cells (APCs) (1-3). Upon stimula-
tion with IFN- , STAT-1 triggers CIITA expression through
interferon- activation sequence (GAS) elements present with-
in the CIITA promoter (4). Because CIITA does not bind
DNA directly, CIITA must exert its effects through interac-
tion with other proteins bound to the conserved elements
within the MHC class II (MHC II) promoter. CIITA binds
to the NF-Y and RFX heterodimers and is believed to sta-
bilize the minimal MHC class II enhanceosome, which pro-
motes the recruitment of general transcription factors, RNA
polymerase II, and various coactivators including CBP to
stimulate expression of the MHC II molecules (5). Although
CIITA was initially described as a master regulator of MHC
class II transcription, it is now clear that it can both activate
and suppress transcription of several genes such as collagen
(6), matrix metalloproteinase-9 (7), IL-4 (8), Fas ligand (9)
and thyroid specific genes (10, 11). Therefore it seems that
the CIITA protein interacts with a variety of transcription
factors in the cells and would be involved in diverse functional
aspects of immune responses in vivo. 
In addition to its control over expression of various genes
including MHC class II, CIITA has also been postulated to
participate in CD4
+Th cell differentiation. For example, CD4
+
T cells from CIITA
-/- I-E-transgenic mice produced enhanced
levels of IL-4 and other Th2-type cytokines upon activation
(12). A subsequent experiment has suggested that the com-
petition between CIITA and NF-AT for binding to CPB/p300
is critical for the suppression of IL-4 transcription by T cells
(8). These results supported the notion that CIITA could be
a Th1-specific factor that functions as a direct repressor of IL-4
expression. However, our previous results obtained from CII-
TA-transgenic mice (Dlck-CIITA Tg) were contradictory to
the previous ones, in that CD4
+ T cells from the Dlck-CIITA
Tg mice, in which the CIITA expression is restricted to peri-
pheral T cells, exhibited a low level of IFN- secretion as well
as impaired Th1 polarization in vitro, while IL-4 secretion
was enhanced under the Th2 condition (13). Moreover, devel-
opment of experimental autoimmune encephalomyelitis (EAE),
a prototype of Th1-mediated disease, was repressed in the
Dlck-CIITA Tg mice (13). Otten et al. reported that consti-
tutive expression of CIITA in all organs including T cells led
to Th2 bias during Th activation and differentiation (14). All
together, it could be suggested that overexpression of CIITA
in T cells inhibits Th1 differentiation both in vivo and in vitro.
To clarify the discrepancies between the results obtained from
CIITA deficient mouse and CIITA overexpressing mice regard-
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Overexpression of CIITA in T Cells Aggravates Th2-Mediated Colitis
in Mice
The MHC class II transactivator (CIITA) is the master transcriptional regulator of genes
involved in MHC class II restricted antigen presentation. Previously we suggested
another role of CIITA in Th1/Th2 balance by demonstrating that forced expression
of CIITA in murine T cells repressed Th1 immunity both in vitro and in vivo. However,
the results were contradictory to the report that CIITA functioned to suppress the
production of Th2 cytokine by CD4
+ T cells in CIITA deficient mice. In this study, we
investigated the influence of constitutive expression of CIITA in T cells on Th2 immune
response in vivo using murine experimental colitis model. In the dextran sodium
sulfate-induced acute colitis, a disease involving innate immunity, CIITA transgenic
mice and wild type control mice showed similar progression of the disease. How-
ever, the development of oxazolone-induced colitis, a colitis mediated by predomi-
nantly Th2 immune response, was aggravated in CIITA-transgenic mice. And, CD4
+
T cells from the mesenteric lymph node of CIITA-transgenic mice treated with oxa-
zolone exhibited a high level of IL-4 secretion. Together, these data demonstrate
that constitutive expression of CIITA in T cells skews immune response to Th2, result-
ing in aggravation of Th2-mediated colitis in vivo.
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ing the role of CIITA function in Th differentiation, immune
reaction induced under Th2 condition should be tested in
the CIITA transgenic mice.
Abnormal mucosal T cell responses are related to the devel-
opment of human inflammatory bowel diseases (IBD), such as
Crohn’s disease and ulcerative colitis. Among the diseases, the
development of Crohn’s disease has been known to be based
on Th1 response, while the ulcerative colitis has been regard-
ed as a representative Th2 response-mediated disease. The
Th2-mediated colitis could be induced in mouse models by
the intrarectal administration of the haptenating agent oxa-
zolone in an ethanol vehicle (15, 16).
To determine whether CIITA could indeed play a role in
promotion of Th2 response in vivo, we induced experimental
colitis with oxazolone using Dlck-CIITA-transgenic (CIITA
Tg) mice with restricted expression of CIITA gene in T cells.
And we show here that administration of oxazolone induced
more severe colonic inflammation in the CIITA Tg mice, im-
plying that Th2 dependent immunity is enhanced.
MATERIALS AND METHODS
Mice
The generation of CIITA transgenic mice on C57BL/6 (B6)
background was previously described (13). C57BL/6 mice
were purchased from Daehan Biolink (Chungbuk, Korea).
All mice were housed in a specific pathogen-free facility in
Hallym University. All experimental animals were cared for,
maintained, and terminated by CO2 inhalation in accordance
with the Hallym University Guideline.
Dextran sodium sulfate-induced colitis
Colitis was induced in CIITA-transgenic mice and litter-
mate wild type B6 mice by addition of 2.5% DSS (dextran
sodium sulfate M.W. 36,000-50,000; MP Biomedicals, Irvine,
CA, U.S.A.) to drinking water for 12 days. Control mice re-
ceived drinking water only. Animals were monitored daily
for loss of body weight, and survival for 12 days. On day 7
after starting DSS administration, when clinical symptoms
such as diarrhea, hematochezia, and weight loss were obvi-
ous, mice were sacrificed and colon length was recorded.
Oxazolone-induced colitis
Colitis was induced in CIITA-transgenic mice and litter-
mate wild type B6 mice as previously described (16). In brief,
mice were sensitized by the epicutaneous application of 200
L of 3% (w/v) oxazolone (4-ethoxymethylene-2-phenyl-2-
oxazoline-5-one, Sigma-Aldrich, St Louis, MO, U.S.A.) solu-
tion onto the shaved abdomens. Five days after presensitiza-
tion, mice were rechallenged intrarectally with 150  L 1%
oxazolone in 50% ethanol or only 50% ethanol (i.e., vehicle)
under light anesthesia. Intrarectal injection was administrated
with a 3.5 F catheter. Animals were monitored daily for loss of
body weight, and survival for 7 days. At 3 days after oxazolone
administration, when the difference between the degree of
weight loss of wild type and that of CIITA transgenic mice was
peak, mice were sacrificed and colon length was recorded.
Cell isolation and cytokine production
Mouse CD4
+T cells were harvested from mesenteric lymph
nodes of CIITA-transgenic or littermate mice by Ficoll-Paque
(Amersham Bioscience, Buckinghamshire, U.K.) gradient
centrifugation of lymphocytes and magnetic cell sorting using
MACS with anti-CD4 (GK1.5) microbeads (Miltenyi Biotec,
Bergisch Gladbach, Germany) as recommended by the manu-
facturer. The purity of collected CD4
+T cells was determined
by flow cytometry using anti-CD4 mAb (GK1.5) and ranged
from 95 to 97%. The purified CD4
+ T cells were stimulated
with anti-CD3 mAb (2C11) and 50  g/mL mitomycin-C
treated splenocytes in RPMI medium (Amersham Bioscience)
supplemented with 10% fetal bovine serum (HyClone, Logan,
UT, U.S.A.) and 50  M  -mercaptoethanol for 3 days. ELISA
used the culture supernatants for cytokine assay.
Cytokine ELISA
Quantitative analysis of cytokines in cell culture supernatants
was performed by sandwich ELISA using the OptEIA kits
(Pharmingen, San Diego, CA, U.S.A.).
Histopathological analysis
Colons were removed, fixed in 10% neutral formalin, em-
bedded in paraffin, sectioned at 4  m and stained with hema-
toxylin and eosin (H&E). The severity of lesion was compared
among each group by light microscopic examination.
Statistical analysis
Comparison of the mean cytokine secretion between wild-
type and CIITA-transgenic mice were analyzed by the Mann-
Whitney’s rank sum test. Comparison of the body weight
between two groups was done by two-way ANOVA. p val-
ues less than 0.05 were considered statistically significant.
RESULTS
CIITA expression on T cells does not affect DSS-induced
colitis
Administration of DSS dissolved in water to mice induces
acute colitis that occurs while the DSS is administered, andTh2 Colitis in CIITA-Transgenic Mice 879
chronic colitis a little time after the administration (17). First,
we investigated the effect of CIITA expression in T cells on
the course of development of DSS-induced acute colitis. The
average weights of the C57BL/6 wild type mice and CIITA-
Tg mice on day 0 rights before the DSS administration were
22.9±1.4 g and 23.6±0.9 g, respectively. Then body weight
was monitored for following 7 days, and histopathologic fea-
tures were evaluated with tissue samples on day 7. Clinical
symptoms of acute colitis such as a progressive loss of body
weight (32.72±0.02% decreases compared with control
group treated with water), hematochezia, and diarrhea were
noted in the DSS-administered mice; loose stool was detected
from day 4 and diarrhea and hematochezia were noted after the
5th day following administration of 2.5% DSS. CIITA-Tg
mice showed similar pathway of acute colitis development
after DSS administration and the extent of loss of body weight
was comparable with that observed in normal mice treated
with DSS (Fig. 1). Histopathologic examination of the colon
on day 7 after DSS administration showed massive infiltration
of mixed inflammatory cells in mucosa and submucosa with
epithelial denudation, destruction of crypt architecture, and
ulceration (Fig. 2). Pathologic changes in colon induced by DSS
administration for 7 days were similar in wild type and CIITA
Tg mice (Fig. 2), implying that CIITA expression in T cells
did not influence the development of DSS-induced colitis.
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Fig. 1. Overexpression of CIITA expression in T cells did not affect
DSS-mediated colitis. Wild type (WT) and CIITA-transgenic (Tg)
mice were treated with 2.5% DSS for 7 days and body weight was
monitored every day. DSS significantly reduced body weight for
7 days; this decrease in body weight was not affected by CIITA
expression in T cells. Each point represents average weight data.
The standard errors are indicated.
Fig. 2. Histopathological features of wild type and CIITA-transgenic
mouse intestines showing similar inflammation in response to DSS
treatment. Colonic samples were taken both from wild type (WT)
and CIITA-transgenic (Tg) mice receiving either water (control) or
DSS on day 7. Compared with that of control animals (left), colons
of DSS-treated mice (right) shows complete destruction of epithe-
lial architecture, with nearly complete loss of crypts, loss of epithe-
lial integrity, and intense cellular inflammation in all layers. CIITA
expression (right lower) does not affect morphological damage
and colonic inflammation shown in these mice is comparable to
that of wild type mice (right upper). (H&E stain, ×100).
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Fig. 3. Overexpression of CIITA in T cells aggravated the development of oxazolone-induced colitis. (A) Weight changes of wild type (WT)
and CIITA-transgenic (Tg) mice treated with 50% ethanol alone or oxazolone in 50% ethanol. Mice were initially presensitized with epicu-
taneous application of oxazolone, followed by intrarectal administration of 1% oxazolone. After initial reduction of the body weight in both
oxazolone-treated groups, the WT mice showed rapid increase in the average body weight after day 2, compared with that of CIITA-trans-
genic (Tg) mice. Each point represents average weight data pooled from 9 or 15 mice. The standard errors are indicated. (B) Survival of
wild type mice treated with oxazolone was similar to that of CIITA-transgenic mice treated with oxazolone. *, p<0.05; 
� , p<0.01
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Aggravation of the colitis induced by oxazolone in CIITA-
transgenic mice
Next, we tested whether the over-expression of CIITA in
peripheral T cells might influence Th2 immune response in
vivo. Administration of oxazolone per rectum in the presence
of ethanol induces a mucosal immune response leading to a
rapidly developing colitis confined to the distal half of the
colon in susceptible (SJL and C57BL/6) mouse strains (15).
In this model, the inflammation is characterized by increased
IL-4 and IL-5 secretion and the inflammation can be amelio-
rated by the administration of anti-IL-4 antibodies (15). CIITA-
Tg mice and wild type littermates were sensitized by the epi-
cutaneous application of 3% oxazolone solution onto the shav-
ed abdomens, followed by administration of 1% oxazolone
per rectum 5 days later. While control animals, which received
50% ethanol in PBS, appeared to have only a transient weight
loss without morbidity, oxazolone-challenged B6 mice devel-
oped colitis, showing more severe weight loss that peaked 1
day after induction and sometimes culminated in death by
day 3 (Fig. 3). This was accompanied by shortening of colonic
length; 49±4 mm and 62±4 mm in oxazolone- and vehi-
cle-treated mice, respectively. Microscopic examination of
colon extracted from these mice on day 3 after oxazolone chal-
lenge per rectum showed histological evidence of severe col-
itis, which involved only the distal half of the bowel. Oxazo-
lone-treated mice developed dense infiltration of the mucosa
with small polynuclear granulocytes and lymphocytes (Fig.
4B). These clinical and pathologic features of oxazolone-in-
duced colitis were significantly aggravated in CIITA-Tg mice.
Treatment with oxazolone per rectum led to more severe weight
loss and slow recovery in weight loss (Fig. 3A) in the CIITA-
Tg mice, although survival rate was not statistically different
from that of wild type littermate (p=0.37) (Fig. 3B). Macro-
scopically, the length of the colon in the oxazolone-treated
CIITA Tg group (37±3 mm) was shorter than that in the
wild type group treated with oxazolone (49±4 mm) (Fig.
4A). Histological findings showed significantly higher num-
ber of inflammatory cells infiltrating from mucosa to serosa
of the colons in oxazolone-treated CIITA-Tg mice, compared
with wild type controls (Fig. 4B).
As oxazolone-induced colitis is a representative Th2 cell-
mediated process, we compared Th1 and Th2 cytokine secre-
tion by CD4
+ T cell from CIIT-Tg mice and wild type litter-
mates. When the CD4
+T cells isolated from mesenteric lym-
ph nodes of CIITA-Tg or wild type mice undergoing oxazo-
lone-induced colitis were stimulated with anti-CD3 antibody
in ex vivo, CD4
+ T cells isolated from CIITA Tg mice pro-
duced larger amount of Th2 cytokine, IL-4 but lower level
of IFN- than those from wild type mice (Fig. 5).
Thus, compared with DSS-induced colitis, the over-expres-
sion of CIITA in peripheral T cells clearly showed an adverse
effect on the inflammation induced by treatment of oxazolone
in colons, which is associated with the Th2 bias in CIITA-
expressing CD4
+ T cells. 
DISCUSSION
Besides its function as a key regulator for the expression of
MHC class II molecule (1, 2), CIITA has been known to play
additional roles in Th differentiation and activation-induced
cell death (8, 9, 12, 14, 18). Previously, we have shown that
the constitutive expression of CIITA in mature T cells sup-
Fig. 4. Gross and microscopic features of intestines showing aggra-
vated inflammation in CIITA-transgenic (Tg) mice compared with
wild type (WT) mice in response to oxazolone. (A) Treatment with
oxazolone induced significant shortening of the colon, which was
more significant in CIITA-transgenic mice. (B) Histology of colonic
samples taken from mice receiving oxazolone. Colon from oxazo-
lone-treated CIITA-transgenic mice on day 3 after the challenge
of oxazolone per rectum shows more severe inflammation charac-
terized by epithelial ulceration, destruction of glands and inflam-
matory cell infiltration in whole layer of bowel wall (right). While in
oxazolone treated wild type mice (left), the colon shows restrict-
ed inflammatory cell infiltration to mucosa. (H&E stain, ×100).
Fig. 5. Altered cytokine production from CD4
+ T cells in CIITA-trans-
genic mice with oxazolone-induced colitis. CD4
+ T cells were iso-
lated from mesenteric lymph node of wild type (WT) and CIITA-
transgenic (Tg) mice on day 3 after induction of oxazolone colitis
and stimulated in vitro for 3 days with anti-CD3 antibody (2C11).
The levels of cytokines secreted in culture supernatant were deter-
mined by ELISA.
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Using the same CIITA-Tg mice, we tested the effect of CIITA
in Th2-differentiation in vivo. In this study, we showed that
forced expression of CIITA in T cells enhanced Th2 immu-
nity, which was confirmed by the increased susceptibility of
CIITA-Tg mice to oxazolone-induced colitis, a Th2-mediated
IBD model.
Recently, the contradictory results, whether CIITA inhibits
Th2 differentiation or Th1 differentiation, obtained from
CIITA knock-out mice or CIITA transgenic mice, respective-
ly were reported. The function of CIITA in Th differentiation
was first demonstrated by the observation of increased gener-
ation of IL-4 secreting CD4
+ T cells in CIITA
-/-I-E-transgenic
mice (12). Treatment of purified protein derivative (PPD) of
Mycobacterisum bovis induced smaller granuloma in the CIITA
-/-
I-E-transgenic mice, development of which depends on the
ability to generate a Th1-dominated immune response (19),
than the granuloma in PPD-treated control mice (12). The
IFN- levels were comparable between the two groups of
mice, indicating that PPD-specific T cells had differentiated
into Th1 by the sensitization. Therefore, Gourley et al. has
suggested that the decrease in the granuloma size in the CII-
TA
-/-I-E-transgenic mice might be due to the elevated IL-4
production, not a decrease in the IFN- level. In addition, a
transfection study has shown that CIITA might suppress IL-
4 transcription in Th1 cells by competing with NF-AT for
binding to the general coactivator CBP (8). These data pre-
dict that the over-expression of CIITA in T cells should lead
to the suppressed Th2 differentiation and an enhanced Th1
differentiation of the CIITA-Tg cells upon activation. How-
ever, the data shown by Otten et al. and our group were in
sharp contrast with the prediction, in that the two indepen-
dent CIITA-Tg mice (ectopic expression of CIITA in all types
of cells in the body and restricted expression of the molecule
in mature T cells, respectively) rendered the transgenic CD4
+
T cells to differentiate preferentially into IL-4 secreting Th2-
type cells in vitro (13, 14). Our interpretation on the contro-
versy is that the previous studies on the function of CIITA in
peripheral CD4
+ T cells from CIITA-deficient and -transgenic
mice have focused largely on repression of Th1 immunity in
vivo, while Th2 bias was checked via in vitro studies. In cur-
rent study, we evaluated the effect of CIITA expression in
mature CD4
+ T cells on innate and Th2 immune response
in vivo using DSS- or oxazolone-induced colitis model.
The administration of DSS dissolved in water to mice caused
hematochezia, body weight loss, shortening of the intestine,
mucosal ulcers, and infiltration of neutrophils (17). This acute
colitis, which occurred during the administration of DSS, was
considered to be induced by innate immunity, but not ac-
quired immunity (20). Based on our results, CIITA expres-
sion in T cells did not have any influence on the DSS-induced
innate immunity, acute colonic inflammation, resulting in
similar progression of the disease both in CIITA Tg and B6
wild type mice.
Oxazolone-induced colitis is easily distinguishable from
most other forms of experimental colitis. First, it is a rapid
onset inflammation that peaks within a few days after oxazo-
lone administration and leads to wasting and bloody diarrhea,
resulting in the death of the mouse, otherwise complete recov-
ery. Second, oxazolone-induced colitis is marked by inflam-
mation strictly limited to the distal half of the colon. At the
microscopic level, the inflammation of oxazolone-induced
colitis is relatively superficial and is characterized by ulcera-
tion, cellular exudates, and a mixed inflammatory infiltrate
of lymphocytes, granulocytes, and eosinophils. Third, and
perhaps most importantly, in oxazolone-induced colitis, the
T cell response is accompanied by markedly elevated IL-4 pro-
duction and prevented by the systemic co-administration of
anti-IL4 antibody (15). Thus the oxazolone-induced colitis
is a suitable model of colitis for evaluation of the CIITA effect
on IL-4 production and Th2 inflammation in vivo that has
features resembling the human disease, ulcerative colitis. As
we expected, oxazolone-induced colonic inflammation was
aggravated in CIITA-Tg mice (Fig. 3, 4), confirming that
the CIITA expression in CD4
+ T cells tends to bias CD4
+ T
cell response into Th2 .
In summary, the results shown in current study, when con-
sidered in conjunction with our previous results (13), provide
additional support for the view that the constitutive expres-
sion of CIITA in T cells inhibits Th1 differentiation and pro-
mote Th2 differentiation both in vitro and in vivo.
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